for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

BRIEF-Astrazeneca Says Forxiga Cardiovascular Outcomes Benefit Approved In China

Oct 28 (Reuters) - AstraZeneca Plc:

* FORXIGA CV OUTCOMES BENEFIT APPROVED IN CHINA

* UPDATE TO APPROVAL INCLUDES DECLARE-TIMI 58 PHASE III TRIAL THAT REDUCED RISK

* CHINA’S NMPA HAS UPDATED LABEL FOR ASTRAZENECA’S FORXIGA (DAPAGLIFLOZIN) TO INCLUDE DATA FROM DECLARE-TIMI 58 PHASE III TRIAL. Source text for Eikon: Further company coverage:

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up